Nasal Vaccine Gets Approval for Booster Doses
Bharat Biotech’s intranasal vaccine will be used in India’s Covid-19 vaccination programme. On December 23, 2022, Union Health Minister Mansukh Mandaviya said the vaccine was...
Tag : Bharat Biotech
Covaxin Approved for Restricted Emergency Use in Children Aged 6-12 Years
The Drug Controller General of India (DCGI) has granted Bharat Biotech’s Covaxin a limited emergency use authorization for children aged 6 to 12 years. The...
DGCI Permits Bharat Biotech For Intranasal Booster Trial
The Drugs Controller General of India (DCGI) granted permission to Bharat Biotech to start conducting booster dose trials for its intranasal coronavirus vaccine. The approval...
Bharat Biotech Updates Covaxin Efficacy to 65.2%
Bharat Biotech has updated the efficacy of Covaxin to 65.2 per cent against the Delta variant in Effectiveness Study on Delta Variant Lancet Infectious Diseases,...
Bharat Biotech Finishes Phase 2/3 Trials of Paediatric Covaxin
Bharat Biotech has finished the Phase 2/3 trials of the Covaxin for kids under 18 years of age and will submit the data by next...
Covid Nasal Vaccine Gets Nod For Phase 2/3 Trials
Bharat Biotech has got a nod from the Central Drugs Standard Control Organisation(CDSCO) to conduct Phase 2/3 trials of its nasal Covid-19 vaccine. Phase 1...
Cipla Gets DGCI Permission to Import Moderna’s Vaccine
Cipla, a multinational pharmaceutical company headquartered in Mumbai, on Tuesday received approval from the Drugs Controller General of India (DCGI) to import Moderna’s coronavirus vaccine...
Covaxin to be Approved by Oct for Kids: AIIMS Chief
As the threat of the third wave of Covid-19 appears large over India, the AIIMS Chief expects approval of the Covaxin coronavirus vaccine for children...
FDA Rejects Ocugen’s Application of Covaxin
The US Food and Drug Administration (FDA) has rejected the proposal for emergency use authorization (EUA) of Bharat Biotech’s Covaxin. Ocugen, which has done a...
Ocugen Pays $15 Million to Bharat Biotech for Covaxin Rights
Ocugen Inc, the US partner for Bharat Biotech‘s Covid-19 vaccine has announced the payment of $15 million to Bharat Biotech for the vaccine rights in...